CAMP4 Therapeutics wins EU approval to start SYNGAP1 Phase 1/2 trial
CAMP4 Therapeutics has received Clinical Trial Application approval from regulatory authorities and ethics committees across multiple EU member states for its Phase 1/2 ASCEND study of CMP-002, an antisense oligonucleotide designed to treat SYNGAP1-related disorder. The Watertown, Massachusetts company said it now holds clearances in four jurisdictions and expects to dose its first patient before the end of 2026.
The EU approval follows authorisations from Australia's Therapeutic Goods Administration in July 2026, Argentina's ANMAT in the same month, and the UK's Medicines and Healthcare products Regulatory Agency in September 2026. Together, these green lights give CAMP4 a global trial footprint that the company says will allow more affected families to access a trial site without travelling abroad.
The candidate and the disease
CMP-002 is an intrathecally administered ASO designed to bind to a SYNGAP1-specific regulatory RNA, upregulating expression of the SYNGAP1 gene and restoring SYNGAP protein levels toward a near-normal range. SYNGAP1-related disorder arises from haploinsufficiency: a single defective copy of the SYNGAP1 gene leaves patients with roughly half the normal protein level. The condition affects an estimated 10,000 individuals in the United States alone and carries a heavy burden: intellectual disability is present in all patients, epilepsy in approximately 85%, severe behavioural problems in around 70%, and about 30% of patients are non-verbal. No approved disease-modifying therapy currently exists for the condition.
Preclinical data reported by the company include dose-dependent increases in SYNGAP protein in patient-derived neurons, reversal of behavioural phenotypes in a humanised mouse model, statistically significant improvement in seizure parameters in a chemically induced seizure model, and broad brain distribution with protein upregulation in non-human primates. These are encouraging signals, though the translation from animal models to human patients in CNS rare disease has historically proved difficult.
President and chief executive Josh Mandel-Brehm said the expanded global footprint of ASCEND gives more families the opportunity to participate closer to home, and emphasised that enrolment is now the near-term priority for a condition where patients currently have no approved disease-modifying options.
Market context and competitive landscape
The rare paediatric CNS space has attracted growing interest from both established and emerging RNA-targeting companies. Antisense approaches have already demonstrated proof of concept in spinal muscular atrophy, with Ionis Pharmaceuticals' nusinersen establishing the intrathecal ASO route as a viable modality for CNS indications. More recently, a number of companies have applied similar regulatory RNA-targeting logic to haploinsufficiency disorders, including Dravet syndrome and SHANK3-related conditions. CAMP4 itself has disclosed a SHANK3 programme in early discovery.
For SYNGAP1 specifically, the field remains small and early-stage. The condition has orphan-disease status in major markets, which affords CAMP4 accelerated regulatory pathways and potential priority review vouchers in both the US and EU. Investors will be watching the ASCEND trial's safety and tolerability data from the Phase 1 portion closely, as that will shape the probability-of-success assumptions for a broader Phase 2 expansion and any eventual partnership or licensing conversations.
With cash runway and enrolment pace the two variables most likely to move the stock in the near term, the Q4 2026 first-dosing milestone, if met, would represent a tangible proof point for a platform that CAMP4 says is applicable to more than 1,200 haploinsufficient and recessive partial loss-of-function disorders.